Pickkers P, et al. – In this study, researchers assessed whether the use of human recombinant alkaline phosphatase improves kidney function in critically ill patients with sepsis-associated acute kidney injury. For this purpose, they performed a randomized, double-blind, placebo-controlled, dose-finding adaptive phase 2a/2b trial enrolling 301 adults, the optimal therapeutic dose of recombinant alkaline phosphatase was 1.6 mg/kg. Addition of this dose for 3 days to standard care resulted in no statistically significant increase in endogenous creatinine clearance. Findings, therefore, suggested that treatment with human recombinant alkaline phosphatase leads to no improved kidney function in the first week of treatment in this study population.